Mountain View, CA-based 23andMe is moving beyond its roots as a provider of consumer genetic tests, reports Xconomy's Luke Timmerman. The company has been targeting a new customer base, drug companies, which can tap the firm's database of 75,000 people for research purposes. "We still give people access to their genetic information," 23andMe CEO Anne Wojcicki said during a May 15 talk at a conference in Seattle. "But a lot more than that, we are really a research company." Story